Prime Capital Investment Advisors LLC Cuts Stake in Edwards Lifesciences Corporation $EW

Prime Capital Investment Advisors LLC cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 28.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,871 shares of the medical research company’s stock after selling 1,127 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $225,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in EW. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth $27,000. Global X Japan Co. Ltd. grew its stake in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after purchasing an additional 216 shares during the period. Tradewinds Capital Management LLC grew its stake in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after purchasing an additional 205 shares during the period. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EW. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Monday, September 22nd. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $74.02 on Monday. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.00. The stock has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a P/E/G ratio of 3.55 and a beta of 1.05. The firm’s 50-day moving average is $78.09 and its two-hundred day moving average is $76.17. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the company earned $0.70 EPS. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.